New drug ProAgio enters human testing for Tough-to-Treat pancreatic cancer
Disease control
Ongoing
This is the first human study to test the safety of an experimental drug called ProAgio in people with advanced solid tumors, including pancreatic cancer, that have stopped responding to standard treatments. The main goal is to find a safe dose for future studies by giving ProAgi…
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC